Abstract | BACKGROUND: Improving quality of life is considered to be a major endpoint and motivation for clinical intervention in patients with perennial allergic rhinitis (PAR). In addition to classical symptoms of congestion, pruritus, and rhinorrhea, patients will often complain of not being able to sleep well at night and of feeling fatigued during the day. Like sleep apnea, PAR has also been shown to cause sleep disturbance and consequently worsen daytime fatigue and somnolence. HYPOTHESIS: METHODS: Twenty-two subjects were enrolled in a double-blind, placebo-controlled, crossover study using Baalam's design. Patients were treated with either budesonide 128 g/day or placebo. Subjective data include the Epworth Sleepiness Scale, Functional Outcomes of Sleep Questionnaire, Rhino- conjunctivitis Quality of Life Questionnaire, and a daily diary recording nasal symptoms, sleep problems, and daytime fatigue. RESULTS: The results illustrated that the topical nasal corticosteroid significantly improved daytime fatigue (P = 0.03), somnolence (P = 0.02), and quality of sleep (P = 0.05) compared to placebo in patients suffering from PAR. SUMMARY:
|
Authors | K Hughes, C Glass, M Ripchinski, F Gurevich, T E Weaver, E Lehman, L H Fisher, T J Craig |
Journal | Allergy
(Allergy)
Vol. 58
Issue 5
Pg. 380-5
(May 2003)
ISSN: 0105-4538 [Print] Denmark |
PMID | 12797340
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Inflammatory Agents
- Glucocorticoids
- Budesonide
|
Topics |
- Administration, Topical
- Adult
- Anti-Inflammatory Agents
(therapeutic use)
- Budesonide
(therapeutic use)
- Cross-Over Studies
- Disorders of Excessive Somnolence
(drug therapy, etiology)
- Double-Blind Method
- Female
- Glucocorticoids
- Humans
- Male
- Middle Aged
- Nasal Obstruction
(complications, drug therapy, etiology)
- Quality of Life
- Rhinitis, Allergic, Perennial
(complications, drug therapy)
- Surveys and Questionnaires
- Treatment Outcome
|